Addendum
Pembrolizumab (head and neck squamous cell carcinoma, neoadjuvant and adjuvant) – Addendum to Project A25-148
Report documents
-
Addendum
Pembrolizumab (head and neck squamous cell carcinoma, neoadjuvant and adjuvant) – Addendum to Project A25-148
Dossier assessment
Indication:
Adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumours express programmed death-ligand 1 with a combined positive score ≥ 1
Result of dossier assessment:
- Patients with a high postoperative risk profile for whom cisplatin-based therapy is suitable, or with a low postoperative risk profile; neoadjuvant and adjuvant therapy: unchanged after addendum: hint of a minor added benefit
- Patients with a high postoperative risk profile for whom cisplatin-based therapy is not suitable; neoadjuvant and adjuvant therapy: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
21-05-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-41
- Commission
- Commission awarded on 08.04.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-41_en
Connected Projects
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed